Virax Biolabs Signs Three Distribution Deals for ImmuneSelect in Mainland China

PUBT · 3d ago
Virax Biolabs Signs Three Distribution Deals for ImmuneSelect in Mainland China
  • Virax Biolabs entered three non-exclusive distribution agreements to expand sales of its ImmuneSelect research-use immune profiling products in mainland China.
  • The distributors are AmyJet Scientific, Jiangsu Real-Gen Biotechnology and Zhixi (Shanghai) Biotechnology.
  • The agreements cover specified customer segments across six mainland Chinese markets, extending an existing distributor-led commercial strategy.
  • Initial sales will focus on ELISpot assay plates and antigen-specific peptide pools for infectious disease, vaccine and cellular immunity research.
  • Local distributors will purchase products for resale, supporting expansion while limiting the need for a larger direct sales force.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290730PR_NEWS_USPR_____DA83205) on October 29, 2026, and is solely responsible for the information contained therein.